Muller William J, Levin Myron J, Shin Young Kyoo, Robinson Christine, Quinones Ralph, Malcolm Janet, Hild Elaine, Gao Dexiang, Giller Roger
Department of Pediatrics, Division of Infectious Diseases, University of Washington, Seattle, USA.
Clin Infect Dis. 2005 Dec 15;41(12):1812-6. doi: 10.1086/498151. Epub 2005 Nov 7.
Post-hematopoietic stem cell transplantation (HSCT) adenovirus infections were identified in 31 of 204 consecutive pediatric HSCT patients, 18 of whom had severe manifestations of infection. Cidofovir treatment led to clinical improvement in 8 of 10 patients with severe infection and to virologic clearance in 9 patients. In vitro susceptibility to cidofovir was demonstrated in 12 clinical adenovirus isolates. Cidofovir is a promising treatment option for this population.
在204例接受造血干细胞移植（HSCT）的连续儿科患者中，有31例被确诊为移植后腺病毒感染，其中18例有严重感染表现。西多福韦治疗使10例严重感染患者中的8例临床症状得到改善，9例患者实现病毒学清除。12株临床腺病毒分离株显示对西多福韦体外敏感。西多福韦是该人群一种有前景的治疗选择。
